Production (Stage)
Krystal Biotech, Inc.
KRYS
$136.94
$4.323.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.24% | 8.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.24% | 8.70% | |||
| Cost of Revenue | 1.60% | -25.96% | |||
| Gross Profit | -3.52% | 11.71% | |||
| SG&A Expenses | 4.59% | 8.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.51% | 1.74% | |||
| Operating Income | -12.57% | 18.45% | |||
| Income Before Tax | -10.31% | 63.29% | |||
| Income Tax Expenses | 151.17% | 20.93% | |||
| Earnings from Continuing Operations | -21.43% | 67.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.43% | 67.33% | |||
| EBIT | -12.57% | 18.45% | |||
| EBITDA | -12.06% | 18.06% | |||
| EPS Basic | -21.59% | 67.10% | |||
| Normalized Basic EPS | -10.51% | 14.85% | |||
| EPS Diluted | -21.37% | 67.71% | |||
| Normalized Diluted EPS | -10.28% | 15.08% | |||
| Average Basic Shares Outstanding | 0.21% | 0.14% | |||
| Average Diluted Shares Outstanding | -0.04% | -0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||